A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia

Trial Profile

A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs P 1037 (Primary) ; Ivacaftor
  • Indications Primary ciliary dyskinesia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLEAN-PCD
  • Sponsors Parion Sciences; Vertex Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2017 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
    • 14 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
    • 12 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top